MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients

    O. Samotus, M. Jog (London, Canada)

    Objective: To investigate whether Dysport increases waning time compared to other botulinum toxin type A (BoNT-A) formulations for cervical dystonia (CD) therapy. Background: BoNT-A injections…
  • 2022 International Congress

    Dysphagia and its relationship to medication intake in Parkinson’s disease

    B. Labeit, E. Berkovich, I. Claus, M. Roderigo, AL. Schwake, D. Izgelov, D. Mimrod, S. Ahring, S. Oeleberg, P. Muhle, V. Zentsch, F. Wenninger, S. Suntrup-Krueger, R. Dziewas, T. Warnecke (Muenster, Germany)

    Objective: This study attempted to obtain a comprehensive picture of medication intake dysphagia in Parkinson’s disease (PD). Specific investigations included 1) An objective, graduated and…
  • 2022 International Congress

    DystoniaBoTXNet: A Deep Learning Platform for Predictive Outcome of Botulinum Toxin Treatment in Isolated Dystonia

    D. Yao, L. O'Flynn, K. Simonyan (Boston, USA)

    Objective: To develop and validate an objective measure of the botulinum toxin treatment outcome in isolated dystonia. Background: Dystonia is characterized by abnormal, often painful,…
  • 2022 International Congress

    Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

    R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

    Objective: To compare the duration of continuous “On” without troublesome dyskinesia (“Good On”) intervals and number of motor fluctuations per day in Parkinson’s disease (PD)…
  • 2022 International Congress

    Characterization of nociplastic pains in Parkinson’s disease (PD) with the PD pain classification system (PD-PCS)

    V. Mylius, S. Lloret, N. Fisch, R. Gonzenbach, G. Kägi, J. Möller, F. Brugger, D. de Andrade (Valens, Switzerland)

    Objective: To describe the new category of nociplastic pain (NP). We defined Parkinson's disease (PD)-related pains and allocated them to a mechanistic category by using the…
  • 2022 International Congress

    The Parkinson’s Incidence Cohorts Collaboration (PICC): an international collaboration of incident PD cohorts

    A. Macleod, J. Maple-Grødem, M. Camacho, R. Lawson, D. Bäckström, A. Yarnall, C. Williams-Gray, G. Alves, O. Tysnes, L. Forsgren, C. Counsell (Aberdeen, United Kingdom)

    Objective: To (i) identify all incidence cohorts of Parkinson’s disease (PD) with long-term follow up and (ii) pool data from these cohorts to study PD…
  • 2022 International Congress

    Botulinum Toxin A in the Management of peripheral mononeuropathy: post herpetic neuralgia and trigeminal neuralgia

    F. Ortega (guatemala, Guatemala)

    Objective: The purpose of this study is determinate the efficacy and safety of botulin toxin A in the treatment of refractory post herpetic neuralgia and…
  • 2022 International Congress

    Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations

    G. Castilla-Fernández, M. Fonseca, J. Ferreira, J-F. Rocha (Coronado, Portugal)

    Objective: This study compared the effects of catechol-O-methyl transferase (COMT) inhibitors and monoamine oxidase‑B (MAO-B) inhibitors on mean change from baseline to end-of-study in OFF-time…
  • 2022 International Congress

    An Ecologic Study of Aqueous Lead Exposure and Parkinson’s Disease

    G. Schwartz, M. Williamson (Grand Forks, USA)

    Objective: Examine the potential role of lead in water as a risk factor for PD. Background: Studying disease rates in different locations is an established…
  • 2022 International Congress

    TWO-YEAR LONGITUDINAL FOLLOW-UP OF VISUAL ILLUSIONS AND HALLUCINATIONS IN PARKINSON’S DISEASE

    S. Beze, L. Castellani, B. Pereira, F. Chiambaretta, F. Durif, A. Marques (Clermont-Ferrand, France)

    Objective: To determine whether visual illusions (VI) evolve towards visual hallucinations (VH) along the time in Parkinson’s disease (PD), and whether ophthalmological treatment may have…
  • « Previous Page
  • 1
  • …
  • 143
  • 144
  • 145
  • 146
  • 147
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley